# CDFF332A12101 (NCT04895748)

> DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

No report yet. It can be ordered.

- Drugs tested: DFF332; DFF332 plus everolimus; DFF332 plus spartalizumab plus taminadenant
- Indication: advanced/relapsed ccRCC and malignancies with HIF2α stabilizing mutations

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04895748
- Phase: PHASE1
- Status: TERMINATED
- Sponsor: Novartis Pharmaceuticals
- Conditions: Carcinoma, Renal Cell
- Interventions: DFF332; RAD001; PDR001; NIR178
- Enrollment: 40
- Primary outcome: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
- Primary outcome: Number of participants with dose interruptions and dose reductions
- Primary outcome: Dose intensity for DFF332 for dose escalation and expansion
- Primary outcome: Incidence of Dose Limiting Toxicities (DLTs) in Cycle 1 (28 days) for DFF332 as a single agent and in combinations

## Indexed commentary on CDFF332A12101 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=cdff332a12101-nct04895748